Novartis: Atherosclerosis trials

The registry lists 27 Atherosclerosis studies with Novartis as lead sponsor. 4 are open to participants now and 10 have results posted.

Phase 1 1Phase 2 5Phase 3 10Phase 4 3No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabRecruitingNCT07543731
• Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With DyslipidemiaRecruitingNCT07034690Phase 4
• Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in RussiaRecruitingNCT06858332
• LATAM LOWERS LDL-CRecruitingNCT06501443Phase 4
• Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.CompletedNCT05888103Phase 3Results posted
• A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)CompletedNCT04929249Phase 3Results posted
• Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary SyndromeCompletedNCT04873934Phase 3Results posted
• Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced SupportCompletedNCT04807400Phase 3Results posted
• An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High CholesterolCompletedNCT03060577Phase 2Results posted
• Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)CompletedNCT02597127Phase 2Results posted
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)CompletedNCT01327846Phase 3Results posted
• A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)CompletedNCT01156571Phase 3Results posted
• Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT PatientsCompletedNCT00995930Phase 2Results posted
• Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.TerminatedNCT00385138Phase 3Results posted
• A Study of DII235 in Adults With Elevated Lipoprotein(a)Active, not recruitingNCT07235046Phase 2
• Patterns of Inclisiran Use in the Real World: An Analysis of US DatabasesCompletedNCT07023445
• Managed Access Programs for TQJ230, PelacarsenNo longer availableNCT07000695
• Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE StudyActive, not recruitingNCT06958315
• Pelacarsen Roll-over Extension ProgramActive, not recruitingNCT06875973Phase 3
• Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVDActive, not recruitingNCT06813911Phase 3
• A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial HypercholesterolemiaCompletedNCT06507852
• A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.CompletedNCT06431763Phase 4
• In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular DiseaseCompletedNCT05974345
• The Belgian REAL (BE.REAL) RegistryActive, not recruitingNCT05726838
• A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world SettingCompletedNCT05362903
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseActive, not recruitingNCT05030428Phase 3
• Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)CompletedNCT00568594Phase 1/2